Valneva SE

​Valneva SE is a biotech company specialized in infectious diseases and we have 2 globally established commercial vaccines often used by travellers. One is against the deadly Japanese encephalitis disease spread by the Culex mosquito and prevalent in Asia. The other is against cholera and ETEC (Enterotoxigenic Escherichia coli) diarrhea - two different types of diarrhea resulting from consuming contaminated food and water. ETEC is the most common reason why travellers are stricken with diarrhea when travelling to countries in South America, South Asia, and South-East Asia.
 

In our research laboratories, we have a number of propriety vaccines under development including vaccines against Clostridium difficile and Lyme disease. We also have partnerships with leading edge pharmaceutical companies that complements our value proposition. We try to help these companies develop new vaccines using our innovative and validated vaccine technology platforms (EB66 vaccine product cell line, IC31 adjuvant).
 

Valneva was originally incorporated in Lyon, France. We also have operations in Austria, Scotland, UK, Sweden, US and Canada. Today - there are approximately 400 employees who work in Valneva.